Skip to end of metadata
Go to start of metadata

You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 4 Next »

Mifos X is the Intellectual Property; renamed to Apache Fineract and donated to Apache Software Foundation.

License of Mifos X changed from MPL 2.0 to Apache 2.0 during this transition.

Community governance model changed from Mifos Foundation to Apache way.

Most of the project dependent applications are still licensed under MPL 2.0 and maintained by Mifos Foundation.

The project discussions are connected and documentations have been assessed to be highly scattered.

There is an ongoing effort by the Apache Software Foundation PMC to bind the Apache Fineract(Mifos X )to Apache Software Foundation’s governance model, as if the project’s Intellectual Property is entirely owned and controlled by Apache Software Foundation.

  1. Identify whether issues concerning solution licensing, and compatibility with other open source component licenses remain or not, when licensing has changed for Mifos X, from MPL 2.0 to Apache 2.0?

  2. What are the underlying effects on the Intellectual property rights of contributors, after the change in licensing from MPL 2.0 to Apache 2.0?

  3. Is there any open, public litigation against the Mifos Foundation, Apache Software Foundation or Grameen Foundation, in connection to the Intellectual Property or components thereof, assigned between the organisations?

  4. Identify any active, open, or settled Intellectual Property litigations against any of the human stakeholders identified in the case study ?

  5. Identify any active, open financial crimes litigations against any of the human stakeholders identified in the case study ?

  6. Identify any active, open criminal litigations for discrimination and protection of minorities, against any of the human stakeholders identified in the case study ?

  7. Identify any active, open, or closed investigations by the financial regulatory and supervisory bodies against any of the human stakeholders identified in the case study ?

  • No labels